DanCann Pharma A/S: Standardized medicinal cannabis products are essential for the medical profession – and ultimately for the patients

COPENHAGEN, Denmark, 19 August 2022 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) comment on the importance of standardization of medicinal cannabis products

The Danish biopharmaceutical manufacturer DanCann Pharma has established the high-tech production facility, Biotech Pharm1 (“BP1"), in order to be able to produce standardized medicinal cannabis products. The facility is built based on best practice from the pharmaceutical industry in combination with advanced environmentally controlled agricultural technology and vertical agriculture.

BP1 is designed to supply cannabis ingredients to the global market in accordance with EU Good Manufacturing Practice (GMP) standards. BP1 can copy and control microclimatic conditions very closely and accurately without interference from external environmental factors. This provides complete and specific control over all cultivation cells in the facility and makes it possible to mimic unique cultivation conditions in relation to the specific plant genetics. This level of control and precision ensures consistent results, yield and product safety.

Jeppe Krog Rasmussen, CEO of DanCann Pharma, comments:

- DanCann Pharma's cannabis genetics respond extremely well to the unique growth conditions and practices found in BP1. These genetics are the basis of the entire facility, and our products will be completely similar from batch to batch. A standardized cannabis product enables doctors to monitor the dose and the effect of medicinal cannabis in the same way as for other kinds of certified medication. Unlike other medication, the cannabis plant does not have a fixed chemical/molecular composition. Cannabis contains hundreds of different substances, and each individual plant is different in terms of its composition, 

No two cannabis plants are the same. Ultimately, the complete ‘fingerprint’ of the plant determines its effect. THC and CBD are the best-known substances, but there are dozens to hundreds of other known and unknown substances in the plant that may have an effect.

Jeppe Krog Rasmussen elaborates:

- Cannabis must be standardized so that each variety of medicinal cannabis has a unique, fully standardized genetic composition that is and remains the same each time, for every batch, year in, year out, with a systemized and unique production process. The result is that the CBD and THC levels are always the same, but the other substances are also always present in the same ratio. The reproducible chemical profile enables doctors to monitor the dose and the effect on the disorder in the same way as for other certified medication.

Standardized cannabis is extremely important to the patient, because just like ‘normal’ medication, all patients are ‘set’ on a certain variety. Sometimes it can take a long time to get patients on the right variety with exactly the right dose based on the existing varieties. The same applies to the use of cannabis oil. Changing the dose or administering medication with a different genetic composition can have adverse consequences for individual patients.

Jeppe Krog Rasmussen comments:

- Quite rightly, doctors want to know exactly what they give to their patients and what its effects are. It takes a lot of time and effort for doctors to become used to prescribing cannabis. The reproducible chemical profile of standardized medicinal cannabis enables doctors to monitor the dose and the effectiveness in the same way as for other certified medication. As this medicinal cannabis is also produced in accordance with pharmaceutical standards, quality and safety are guaranteed as much as possible.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.